Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart H Cohen

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Open Forum Infectious Diseases|May 19, 2023
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary InfectionsDaniel A Sweeney, Bonifride Tuyishimire, Neera Ahuja, et al.
The New England Journal of Medicine|June 13, 2019
Clinical Metagenomic Sequencing for Diagnosis of Meningitis and EncephalitisMichael R Wilson, Hannah A Sample, Kelsey C Zorn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Open Forum Infectious Diseases|June 29, 2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test CaseAna M Ortega-Villa, Noreen A Hynes, Corri B Levine, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2025
NCCN Guidelines® Insights: Survivorship, Version 2.2025Tara Sanft, Andrew T Day, Shannon M Ansbaugh, et al.
The New England Journal of Medicine|April 11, 2020
Compassionate Use of Remdesivir for Patients with Severe Covid-19Jonathan Grein, Norio Ohmagari, Daniel Shin, et al.
Annals of Internal Medicine|November 28, 2022
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment TrialGail E Potter, Tyler Bonnett, Kevin Rubenstein, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
JAMA Network Open|February 13, 2023
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm TrialMatthew D Sims, Sahil Khanna, Paul Feuerstadt, et al.
Infectious Diseases and Therapy|June 28, 2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDIColleen S Kraft, Matthew Sims, Michael Silverman, et al.
The New England Journal of Medicine|January 19, 2022
SER-109, an Oral Microbiome Therapy for Recurrent <i>Clostridioides difficile</i> InfectionPaul Feuerstadt, Thomas J Louie, Bret Lashner, et al.
Open Forum Infectious Diseases|May 19, 2023
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary InfectionsDaniel A Sweeney, Bonifride Tuyishimire, Neera Ahuja, et al.
The New England Journal of Medicine|June 13, 2019
Clinical Metagenomic Sequencing for Diagnosis of Meningitis and EncephalitisMichael R Wilson, Hannah A Sample, Kelsey C Zorn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 25, 2025
Analysis of antibody markers as immune correlates of risk of severe COVID-19 in the PREVENT-19 efficacy trial of the NVX-CoV2373 recombinant protein vaccineYouyi Fong, Yunda Huang, Ying Huang, et al.
Open Forum Infectious Diseases|June 29, 2023
Evaluating Demographic Representation in Clinical Trials: Use of the Adaptive Coronavirus Disease 2019 Treatment Trial (ACTT) as a Test CaseAna M Ortega-Villa, Noreen A Hynes, Corri B Levine, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2025
NCCN Guidelines® Insights: Survivorship, Version 2.2025Tara Sanft, Andrew T Day, Shannon M Ansbaugh, et al.
The New England Journal of Medicine|April 11, 2020
Compassionate Use of Remdesivir for Patients with Severe Covid-19Jonathan Grein, Norio Ohmagari, Daniel Shin, et al.
Annals of Internal Medicine|November 28, 2022
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment TrialGail E Potter, Tyler Bonnett, Kevin Rubenstein, et al.
Pageof 8